Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: A randomized clinical trial

International Journal of Infectious Diseases

Volumn 16, Issue 4, 2012, Pages

  Hashemi, Seyyed Hamid ^a   Gachkar, Latif ^b   Keramat, Fariba ^a   Mamani, Mojgan ^c   Hajilooi, Mehrdad ^a   Janbakhsh, Alireza ^a   Majzoobi, Mohammad Mehdi ^a   Mahjub, Hossein ^a  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Brucellosis; Doxycycline; Ofloxacin; Rifampin; Streptomycin

Indexed keywords

ANTIBIOTIC AGENT; DOXYCYCLINE PLUS RIFAMPIN; DOXYCYCLINE PLUS STREPTOMYCIN; OFLOXACIN PLUS RIFAMPIN; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; BRUCELLA MELITENSIS; BRUCELLOSIS; CIRCUMORAL PARESTHESIA; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; EPIGASTRIC PAIN; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEARTBURN; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PHOTOSENSITIVITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SWEATING; TREATMENT FAILURE; TREATMENT RESPONSE; URTICARIA;

ADULT; ANTI-BACTERIAL AGENTS; BRUCELLA MELITENSIS; BRUCELLOSIS; DOXYCYCLINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OFLOXACIN; RIFAMPIN; STREPTOMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858286634     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.12.003     Document Type: Article

References (19)

1. Donev D.M. Brucellosis as priority public health challenge in south eastern European countries. Croat Med J 2010, 51:283-284.
2. Moradi A., Norouzi N.A., Talebi B., Erfani H., Karimi A., Bathaei S.J., et al. Evaluation of animal vaccination against brucellosis on human incidence rate in Hamedan Province 2002-2008. J Hamedan Univ Med Sci 2009, 16:44-48.
3. Pappas G., Akritidis N., Bosilkovski M., Tsianos E. Brucellosis. N Engl J Med 2005, 352:2325-2336.
4. Ersoy Y., Sonmez E., Tevfik M.R., But A.D. Comparison of three different combination therapies in the treatment of human brucellosis. Trop Doct 2005, 35:210-212.
5. Pappas G., Christou L., Akritidis N., Tsianos E.V. Quinolones for brucellosis: treating old diseases with new drugs. Clin Microbiol Infect 2006, 12:823-825.
6. Karabay O., Sencan I., Kayas D., şahin I. Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial. BMC Infect Dis 2004, 4:18.
7. Solera J. Treatment of human brucellosis. J Med Liban 2000, 48:255-263.
8. Buzgan T., Karahocagil M.K., Irmak H., Baran A.I., Karsen H., Evirgen O., et al. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis 2010, 14:e469-e478.
9. Joint FAO/WHO expert committee on brucellosis. World Health Organ Tech Rep Ser 1986;740:1-132.
10. Ariza J., Bosilkovski M., Cascio A., Colmenero J.D., Corbel M.J., Falagas M.E., et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med 2007, 4:1872-1878.
11. Solera J., Martinez-Alfaro E., Espinosa A., Castillejos M.L., Geijo P., Rodríguez-Zapata M. Multivariate model for predicting relapses in human brucellosis. J Infect 1998, 36:85-92.
12. Ariza J., Corredoira J., Pallares R., Viladrich P.F., Rufi G., Pujol M., et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis 1995, 20:1241-1249.
13. Al-Hajjaj M.S., Al-Kassimi F.A., Al-Mobeireek A.F., Alzeer A.H. Progressive rise of Mycobacterium tuberculosis resistance to rifampicin and streptomycin in Riyadh, Saudi Arabia. Respirology 2001, 6:317-322.
14. Skalsky K., Yahav D., Bishara J., Pitlik S., Leibovici L., Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ 2008, 336:701-704.
15. Keramat F., Ranjbar M., Mamani M., Hashemi S.H., Zeraati F. A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis. Trop Doct 2009, 39:207-210.
16. Zowghi E., Ebadi A., Yarahmadi M. Isolation and identification of Brucella organisms in Iran. Iranian J Clin Infect Dis 2008, 3:185-188.
17. Hashemi S.H., Keramat F., Ranjbar M., Mamani M., Farzam A., Jamal-Omidi S. Osteoarticular complications of brucellosis in Hamedan, an endemic area in the west of Iran. Int J Infect Dis 2007, 11:496-500.
18. Roushan M.R., Baiani M., Javanian M., Kasaeian A.A. Brucellar epididymo-orchitis: review of 53 cases in Babol, northern Iran. Scand J Infect Dis 2009, 41:440-444.
19. Al-Tawfiq J.A. Therapeutic options for human brucellosis. Expert Rev Anti Infect Ther 2008, 6:109-120.